Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 20;40(6):611-625.
doi: 10.1200/JCO.21.01626. Epub 2022 Jan 5.

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Aaron C Tan  1   2 , Daniel S W Tan  1   2   3
Affiliations
Review

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Aaron C Tan et al. J Clin Oncol. .

Abstract

Lung cancer has traditionally been classified by histology. However, a greater understanding of disease biology and the identification of oncogenic driver alterations has dramatically altered the therapeutic landscape. Consequently, the new classification paradigm of non-small-cell lung cancer is further characterized by molecularly defined subsets actionable with targeted therapies and the treatment landscape is becoming increasingly complex. This review encompasses the current standards of care for targeted therapies in lung cancer with driver molecular alterations. Targeted therapies for EGFR exon 19 deletion and L858R mutations, and ALK and ROS1 rearrangements are well established. However, there is an expanding list of approved targeted therapies including for BRAF V600E, EGFR exon 20 insertion, and KRAS G12C mutations, MET exon 14 alterations, and NTRK and RET rearrangements. In addition, there are numerous other oncogenic drivers, such as HER2 exon 20 insertion mutations, for which there are emerging efficacy data for targeted therapies. The importance of diagnostic molecular testing, intracranial efficacy of novel therapies, the optimal sequencing of therapies, role for targeted therapies in early-stage disease, and future directions for precision oncology approaches to understand tumor evolution and therapeutic resistance are also discussed.

PubMed Disclaimer

Conflict of interest statement

Aaron C. TanHonoraria: Amgen, Thermo Fisher ScientificTravel, Accommodations, Expenses: ASLAN Pharmaceuticals, Illumina Daniel S.W. TanThis author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.Honoraria: Bristol Myers Squibb, Takeda, Novartis, Roche, PfizerConsulting or Advisory Role: Novartis, Merck, Loxo, AstraZeneca, Roche, PfizerResearch Funding: Novartis, GlaxoSmithKline, AstraZenecaTravel, Accommodations, Expenses: Pfizer, Boehringer Ingelheim, RocheNo other potential conflicts of interest were reported.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms